Healthcare Stocks Continue to Hit Records: LLY, AFL, MCK

WallStreet_Tiger
2023-10-12

1. $Eli Lilly(LLY)$ soared to a record high of $613 on October 12th.

Eli Lilly and Novo Nordisk announced that it plans to stop a kidney outcomes clinical trial evaluating Ozempic (semaglutide) in treating patients with type 2 diabetes and chronic kidney disease.

The study’s independent data monitoring committee recommended the trial be halted because results from an interim analysis showed an efficacy level that met pre-specified criteria.

Lilly is also evaluating Mounjaro in a phase 2 study targeting chronic kidney disease.

 

2. $Aflac(AFL)$ climbed to $80.50 on October 12th.

Aflac is a supplemental health and life insurance provider in the US and Japan. The company has been expanding its product offerings to include accidents, disability, and long-term-care insurance.

Over the past year the S&P 500 is higher by 20.51% while AFL has gained 36.37%. AFL earned $7.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 10.6.

3. $Ares Management LP(ARES)$ achieved a record high of $112.15 on October 12th.

 Ares Management has launched the Ares European Strategic Income Fund, an open-ended direct lending fund.

This initiative provides individual investors in Europe and Asia with access to Ares's European direct lending strategy, enhancing their investment opportunities in the region.

4. $Cadence Design(CDNS)$ reached $255.85 on October 12th.

Shares of the maker of hardware and software products for validating chip designs witnessed a gain of 5.62% over the previous month, beating the performance of the Computer and Technology sector with its loss of 1.56%.

5. $McKesson(MCK)$ traded at $461.32 on October 12th.

McKesson, drug distributor, received a target price of $485.00 to $490.00 from Evercore ISI analysts.

6. $Synopsys(SNPS)$ reached a substantial value of $502.66 on October 12th.

Synopsys, the semiconductor company, consistently demonstrated robust financials, boasting a net margin of 18.71% and a return on equity of 18.01%.

 

LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?
Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading. Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss. ------------ Which weight loss drug company is a better buy?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Jeromelim
    2023-10-13
    Jeromelim
    pharma never loose money in whatever narket condition
  • phongy 45
    2023-10-13
    phongy 45
    pharm .. make super profit ... more sick people are good ??
  • IvanChew
    2023-10-13
    IvanChew

    Great ariticle, would you like to share it?

  • XxYxXx
    2023-10-14
    XxYxXx

    Great ariticle, would you like to share it?

  • Sonsonkok
    2023-10-14
    Sonsonkok

    Great ariticle, would you like to share it?

  • WB1996
    2023-10-14
    WB1996

    Great ariticle, would you like to share it?

Leave a comment
12
1768